These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36685586)

  • 1. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
    Guan S; Zhang L; Zhang J; Song W; Zhong D
    Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
    Lopez AT; Geskin L
    Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
    Zhang X; Sui D; Wang D; Zhang L; Wang R
    Front Immunol; 2021; 12():731774. PubMed ID: 34594337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
    Cosimati A; Rossi L; Didona D; Forcella C; Didona B
    J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
    Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment.
    Sugawara A; Koga H; Abe T; Ishii N; Nakama T
    J Dermatol; 2021 Mar; 48(3):401-404. PubMed ID: 33184934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid.
    Wang J; Hu X; Jiang W; Zhou W; Tang M; Wu C; Liu W; Zuo X
    Front Oncol; 2023; 13():1095694. PubMed ID: 36937423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
    Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G
    Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
    Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
    J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
    Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
    Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of bullous pemphigoid following administration of anti-IL-31 receptor A antibody.
    Masuyuki R; Sato E; Imafuku S
    J Dermatol; 2024 Sep; 51(9):1252-1255. PubMed ID: 38507442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid.
    Liu M; Yuan M; Sun W; Li Z; Zhou X; Wang C
    Invest New Drugs; 2023 Dec; 41(6):802-807. PubMed ID: 37773473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
    Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
    JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bullous pemphigoid associated with squamous cell lung carcinoma showing remarkable response to carboplatin-based chemotherapy:  a case report.
    Shrestha P; George MK; Baidya S; Rai SK
    J Med Case Rep; 2022 May; 16(1):184. PubMed ID: 35513831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
    Tsiogka A; Bauer JW; Patsatsi A
    Acta Derm Venereol; 2021 Jan; 101(1):adv00377. PubMed ID: 33426566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.
    Jour G; Glitza IC; Ellis RM; Torres-Cabala CA; Tetzlaff MT; Li JY; Nagarajan P; Huen A; Aung PP; Ivan D; Drucker CR; Prieto VG; Rapini RP; Patel A; Curry JL
    J Cutan Pathol; 2016 Aug; 43(8):688-96. PubMed ID: 27086658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature.
    Kosche C; Owen JL; Sadowsky LM; Choi JN
    Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series.
    Morris LM; Lewis HA; Cornelius LA; Chen DY; Rosman IS
    J Cutan Pathol; 2020 Aug; 47(8):742-746. PubMed ID: 32196722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
    Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
    Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.